 |
|
| |
|
USA
Tel: +1-800-615-0418
Fax: +1-703-722-0731 |
|
|
|
|
| |
|
| |
Management Team
Ross Dunlap - President & Chief Executive Officer
Dr. Emanuel Petricoin, III - Science Director
Dr. Lance Liotta - Science Director
Dr. Joseph Weaver - Medical Director
Ross M. Dunlap
President & Chief Executive Officer
Ross is a founding member of Ceres and the CEO. Ross is responsible for directing strategic and operational activities, technology R&D, product sales and marketing, and all industry collaborations and partnerships. Ross brings over 12 years of experience working in operational and strategic business consulting. He began his career with Arthur Andersen's Business Consulting practice, working with many of the DC region's leading start-up technology companies, developing solutions to establish and maintain critical business operations. Ross also spent five years with Washington Consulting, Inc., a DC based consulting firm, which he helped start up and grow from a three person project into a 100 person operation. Throughout his business career, Ross has worked across a range of industries, technologies, and processes to help organizations successfully achieve operational capability and profitability. Ross graduated from the McIntire School of Commerce at the University of Virginia.
|
Dr. Emanuel Petricoin, III
Science Director
Dr. Petricoin is one of the inventors of the Nanotrap® technology. As a Science Director for Ceres, Dr. Petricoin provides technical guidance and expertise to key components of Ceres Nanosciences' operations and industry collaborations. Dr. Petricoin is currently a professor of Life Sciences and serves as the Co-Director of CAPMM Labs at George Mason University. Dr. Petricoin formerly worked with the FDA where he was the senior investigator in the Office of Cell Tissue and Gene Therapies in the Center for Biologics Evaluation and Research. Dr. Petricoin holds a doctorate in microbiology from the University of Maryland at College Park. Together with Dr. Lance Liotta, he has formed the Center for Applied Proteomics and Molecular Medicine. The Center has formed a unique partnership between George Mason and Inova Health System. George Mason University-Inova Health System Translational Research Centers is a joint initiative to coordinate multiple programs to implement proteomics, nanotechnology, and genomics research in cancer, metabolic syndrome, cardiopulmonary diseases, and neurodegenerative and liver diseases. This initiative comprises the research efforts of three shared centers: the Center for Applied Proteomics and Molecular Medicine; the Center for Biomedical Genomics; and the Center for the Study of Genomics of Liver Diseases. Inova and George Mason have combined efforts to recruit internationally renowned scientists, such as Dr. Liotta and Dr. Petricoin, to work closely with clinical investigators from Inova.
|
Dr. Lance Liotta
Science Director
Dr. Liotta is one of the inventors of the Nanotrap® technology. As a Science Director for Ceres, Dr. Liotta provides technical guidance and expertise to key components of Ceres Nanosciences' operations. Dr. Liotta is currently a professor of Life Sciences and serves as the Co-Director of CAPMM Labs at George Mason University. He was formerly the Chief of the Laboratory of Pathology at NCI's Center for Cancer Research, where he also served as the chief of the center's Tumor Invasion and Metastases section, Deputy Director for Intramural Research, Co-Director, NCI/FDA Clinical Proteomics Program, and chairs the National Institutes of Health Radiation Safety Committee. He earned his medical degree from Case Western Reserve Medical School and also holds a doctoral degree in biomedical engineering from Case Western Reserve University. Dr. Liotta and Dr. Petricoin began their proteomics collaboration in 1997, which led to the formation of the first Interagency Agreement between NCI and FDA to develop and test technologies for proteomic analysis—the study of protein activity in cells—of cancer and other diseases. Their renowned collaboration has produced more than 100 publications and numerous proteomic processes to develop new methods for diagnosis and treatment of diseases. Combining their clinical and research expertise, they invented a new type of protein microarray technology to simultaneously measure multiple protein pathways from a biopsy specimen. Understanding the activity of protein pathways may ultimately lead to personalized medical treatment and significantly impact public health. In addition to their invention and development of new types of protein microarray technologies, they recently have made several seminal discoveries for biomarker-based research that may assist in the diagnosis of cancer and other diseases.
|
Dr. Joseph Weaver
Chief Medical Officer
Dr. Weaver brings over 40 years of experience from a long and distinguished career in cancer-related research and treatment programs. As Chief Medical Officer for Ceres, he will lend his extensive experience as a medical practitioner and business entrepreneur to drive the development of Ceres' core operations and its product development. Dr. Weaver is board certified by the American Board of Internal Medicine in Internal Medicine, Hematology, and Medical Oncology, and by the American Board of Radiology in Radiation Oncology. He is a life member of AMA and holds fellowships in the American College of Physicians and American College of Radiation Oncology. He was a clinical professor of Internal Medicine at the Pensacola Educational Program, and a clinical professor of Radiation Oncology at Eastern Virginia School of Medicine in Norfolk, VA. Since 1993, he has been the Director of Radiation Oncology at Baptist and Gulf Breeze Hospitals in Pensacola, FL. Dr. Weaver has been the head of the Cancer Committee for most of that period, participating in multiple clinical trials both locally, and through an affiliation with H. Lee Moffitt Cancer Center in Tampa, FL. During his tenure in Pensacola, Dr. Weaver cofounded, operated and has continued as a co-partner in a group of four cancer centers in South Alabama, collectively called Gulf Coast Cancer Centers in Foley, Brewton, Monroeville, and Gulf Shores, AL. He also independently founded the South Alabama Oncology Center in Opp, AL.
|
|
|
